How to use neuroimaging biomarkers in the diagnosis framework of neurodegenerative diseases?

Neuroimaging biomarkers, together with CSF biomarkers, are more and more used to support the early and differential clinical diagnosis of neurodegenerative diseases in clinical setting that have access to those techniques. Based on a consensus of multidisciplinary experts leading to a princeps publication in the Lancet Neurology [Chételat et al., Lancet Neurol 2020; 19: 951-62], we proposed a three-arm diagnosis algorithm detailing the optimal combination of biomarkers for the diagnosis of neurodegenerative diseases according to the clinical presentation. The main conclusions of this princeps article are summarized here, including a brief overview of the complementarity of the most validated neuroimaging biomarkers available, and an argued presentation of the proposed diagnosis algorithm. Copyright © 2022 Elsevier Masson SAS. All rights reserved.

Citation

G Chételat. How to use neuroimaging biomarkers in the diagnosis framework of neurodegenerative diseases? Revue neurologique. 2022 May;178(5):490-497

Mesh Tags

Substances

PMID: 35504738

search → result